Key clinical point: Use of preoperative fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is linked to a longer overall survival in patients with stage IIIA or IIIB resectable non—small-cell lung cancer (NSCLC).

Major finding: Among patients who underwent vs did not undergo preoperative ¹⁸F-FDG PET/CT, those with stage IIIB and stage IIIA disease had 20% (adjusted hazard ratio [aHR] 0.80; 95% CI 0.71-0.90) and 10% (aHR 0.90; 95% CI 0.79-0.94) lower risks for mortality, respectively. Patients with stage I-II disease did not have a lower risk for mortality (aHR 1.19; 95% CI 0.89-1.30).

Study details: The data come from a Taiwanese retrospective cohort study of patients with resectable stage I-IIIB NSCLC who underwent (n = 6,754) and did not undergo (n = 6,754) preoperative ¹⁸F-FDG PET/CT.

Disclosures: This study was funded by the Lo-Hsu Medical Foundation and Lotung Poh-Ai Hospital, Taiwan. SY Wu is a member of the Taiwan Radiological Society and Taiwan Society for Therapeutic Radiology and Oncology. The other authors reported no relevant relationships.

Source: Chen W-M et al. Use of preoperative FDG PET/CT and survival of patients with resectable non–small cell lung cancer. Radiology. 2022 (Jun 21). Doi: 10.1148/radiol.212798

Key clinical point: Use of preoperative fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is linked to a longer overall survival in patients with stage IIIA or IIIB resectable non—small-cell lung cancer (NSCLC).

Major finding: Among patients who underwent vs did not undergo preoperative ¹⁸F-FDG PET/CT, those with stage IIIB and stage IIIA disease had 20% (adjusted hazard ratio [aHR] 0.80; 95% CI 0.71-0.90) and 10% (aHR 0.90; 95% CI 0.79-0.94) lower risks for mortality, respectively. Patients with stage I-II disease did not have a lower risk for mortality (aHR 1.19; 95% CI 0.89-1.30).

Study details: The data come from a Taiwanese retrospective cohort study of patients with resectable stage I-IIIB NSCLC who underwent (n = 6,754) and did not undergo (n = 6,754) preoperative ¹⁸F-FDG PET/CT.

Disclosures: This study was funded by the Lo-Hsu Medical Foundation and Lotung Poh-Ai Hospital, Taiwan. SY Wu is a member of the Taiwan Radiological Society and Taiwan Society for Therapeutic Radiology and Oncology. The other authors reported no relevant relationships.

Source: Chen W-M et al. Use of preoperative FDG PET/CT and survival of patients with resectable non–small cell lung cancer. Radiology. 2022 (Jun 21). Doi: 10.1148/radiol.212798

Key clinical point: Use of preoperative fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is linked to a longer overall survival in patients with stage IIIA or IIIB resectable non—small-cell lung cancer (NSCLC).

Major finding: Among patients who underwent vs did not undergo preoperative ¹⁸F-FDG PET/CT, those with stage IIIB and stage IIIA disease had 20% (adjusted hazard ratio [aHR] 0.80; 95% CI 0.71-0.90) and 10% (aHR 0.90; 95% CI 0.79-0.94) lower risks for mortality, respectively. Patients with stage I-II disease did not have a lower risk for mortality (aHR 1.19; 95% CI 0.89-1.30).

Study details: The data come from a Taiwanese retrospective cohort study of patients with resectable stage I-IIIB NSCLC who underwent (n = 6,754) and did not undergo (n = 6,754) preoperative ¹⁸F-FDG PET/CT.

Disclosures: This study was funded by the Lo-Hsu Medical Foundation and Lotung Poh-Ai Hospital, Taiwan. SY Wu is a member of the Taiwan Radiological Society and Taiwan Society for Therapeutic Radiology and Oncology. The other authors reported no relevant relationships.

Source: Chen W-M et al. Use of preoperative FDG PET/CT and survival of patients with resectable non–small cell lung cancer. Radiology. 2022 (Jun 21). Doi: 10.1148/radiol.212798

Key clinical point: Circulating cell-free RNA (cfRNA) of the candidate transcript MORF4L2 demonstrates very good sensitivity and specificity for distinguishing patients with non—small-cell lung cancer (NSCLC) from healthy individuals.

Major finding: A greater concentration of MORF4L2 cfRNA was seen in patients with NSCLC compared with healthy donors (P < .0001). A cutoff value of 537.5 copies/mL of plasma was useful in distinguishing patients with NSCLC from healthy donors with very good sensitivity (0.73; 95% CI 0.61-0.82) and specificity (0.87; 95% CI 0.73-0.96). Low vs high levels of MORF4L2 cfRNA at baseline were associated with a better overall survival (hazard ratio 0.25; P  =  .009).

Study details: The data come from a cohort study of 41 patients with stage IV NSCLC, 38 patients with early-stage (stage I-III) NSCLC, and 39 healthy blood donors.

Disclosures: This study was supported by the European Transcan-2 project CEVIR (Cancer EVolution and Identification of Relapse-initiating cells) and the German Cancer Consortium. M Metzenmacher, JT Siveke, and M Schuler reported ties with ≥1 pharmaceutical companies. The other authors reported no conflicts of interest.

Source: Metzenmacher M et al. The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non-small cell lung cancer. Thorac Cancer. 2022 (Jun 16). Doi: 10.1111/1759-7714.14540

Key clinical point: Circulating cell-free RNA (cfRNA) of the candidate transcript MORF4L2 demonstrates very good sensitivity and specificity for distinguishing patients with non—small-cell lung cancer (NSCLC) from healthy individuals.

Major finding: A greater concentration of MORF4L2 cfRNA was seen in patients with NSCLC compared with healthy donors (P < .0001). A cutoff value of 537.5 copies/mL of plasma was useful in distinguishing patients with NSCLC from healthy donors with very good sensitivity (0.73; 95% CI 0.61-0.82) and specificity (0.87; 95% CI 0.73-0.96). Low vs high levels of MORF4L2 cfRNA at baseline were associated with a better overall survival (hazard ratio 0.25; P  =  .009).

Study details: The data come from a cohort study of 41 patients with stage IV NSCLC, 38 patients with early-stage (stage I-III) NSCLC, and 39 healthy blood donors.

Disclosures: This study was supported by the European Transcan-2 project CEVIR (Cancer EVolution and Identification of Relapse-initiating cells) and the German Cancer Consortium. M Metzenmacher, JT Siveke, and M Schuler reported ties with ≥1 pharmaceutical companies. The other authors reported no conflicts of interest.

Source: Metzenmacher M et al. The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non-small cell lung cancer. Thorac Cancer. 2022 (Jun 16). Doi: 10.1111/1759-7714.14540

Key clinical point: Circulating cell-free RNA (cfRNA) of the candidate transcript MORF4L2 demonstrates very good sensitivity and specificity for distinguishing patients with non—small-cell lung cancer (NSCLC) from healthy individuals.

Major finding: A greater concentration of MORF4L2 cfRNA was seen in patients with NSCLC compared with healthy donors (P < .0001). A cutoff value of 537.5 copies/mL of plasma was useful in distinguishing patients with NSCLC from healthy donors with very good sensitivity (0.73; 95% CI 0.61-0.82) and specificity (0.87; 95% CI 0.73-0.96). Low vs high levels of MORF4L2 cfRNA at baseline were associated with a better overall survival (hazard ratio 0.25; P  =  .009).

Study details: The data come from a cohort study of 41 patients with stage IV NSCLC, 38 patients with early-stage (stage I-III) NSCLC, and 39 healthy blood donors.

Disclosures: This study was supported by the European Transcan-2 project CEVIR (Cancer EVolution and Identification of Relapse-initiating cells) and the German Cancer Consortium. M Metzenmacher, JT Siveke, and M Schuler reported ties with ≥1 pharmaceutical companies. The other authors reported no conflicts of interest.

Source: Metzenmacher M et al. The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non-small cell lung cancer. Thorac Cancer. 2022 (Jun 16). Doi: 10.1111/1759-7714.14540

Key clinical point: The presence of epidermal growth factor receptor (EGFR) mutation is associated with a longer median overall survival (OS) compared with absence of the EGFR mutation in patients with early-stage (stage I-IIIA) non—small-cell lung cancer (NSCLC).

Major finding: The presence vs absence of EGFR mutation was associated with a longer median OS (5.7 vs 4.4 years). The lower risk for all-cause mortality was consistent across all subgroups (stage at diagnosis, age, sex, comorbidity, and surgery receipt), with hazard ratios ranging from 0.48 to 0.83.

Study details: The data come from a Danish population-based cohort study involving 21,282 patients with NSCLC.

Disclosures: This study was funded by AstraZeneca. A Taylor and L Servidio reported being current or former employees of AstraZeneca. V Ehrenstein and K Eriksen are employees of Aarhus University or Aarhus University Hospital. E Jakobsen is an employee of Odense University Hospital.

Source: Ehrenstein V et al. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 (Jun 20). Doi: 10.1002/cam4.4946

Key clinical point: The presence of epidermal growth factor receptor (EGFR) mutation is associated with a longer median overall survival (OS) compared with absence of the EGFR mutation in patients with early-stage (stage I-IIIA) non—small-cell lung cancer (NSCLC).

Major finding: The presence vs absence of EGFR mutation was associated with a longer median OS (5.7 vs 4.4 years). The lower risk for all-cause mortality was consistent across all subgroups (stage at diagnosis, age, sex, comorbidity, and surgery receipt), with hazard ratios ranging from 0.48 to 0.83.

Study details: The data come from a Danish population-based cohort study involving 21,282 patients with NSCLC.

Disclosures: This study was funded by AstraZeneca. A Taylor and L Servidio reported being current or former employees of AstraZeneca. V Ehrenstein and K Eriksen are employees of Aarhus University or Aarhus University Hospital. E Jakobsen is an employee of Odense University Hospital.

Source: Ehrenstein V et al. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 (Jun 20). Doi: 10.1002/cam4.4946

Key clinical point: The presence of epidermal growth factor receptor (EGFR) mutation is associated with a longer median overall survival (OS) compared with absence of the EGFR mutation in patients with early-stage (stage I-IIIA) non—small-cell lung cancer (NSCLC).

Major finding: The presence vs absence of EGFR mutation was associated with a longer median OS (5.7 vs 4.4 years). The lower risk for all-cause mortality was consistent across all subgroups (stage at diagnosis, age, sex, comorbidity, and surgery receipt), with hazard ratios ranging from 0.48 to 0.83.

Study details: The data come from a Danish population-based cohort study involving 21,282 patients with NSCLC.

Disclosures: This study was funded by AstraZeneca. A Taylor and L Servidio reported being current or former employees of AstraZeneca. V Ehrenstein and K Eriksen are employees of Aarhus University or Aarhus University Hospital. E Jakobsen is an employee of Odense University Hospital.

Source: Ehrenstein V et al. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 (Jun 20). Doi: 10.1002/cam4.4946

Key clinical point: Serum level of 25-hydroxyvitamin D (25[OH]D) was inversely associated with albuminuria as an indicator of diabetic nephropathy in patients with type 2 diabetes mellitus (T2D), with the prevalence of macroalbuminuria increasing when the serum 25(OH)D level was <20 ng/mL.

Major finding: A strong negative association was observed between the serum 25(OH)D level and severity of albuminuria (r, −0.257; P < .001), with the prevalence of vitamin D deficiency being 61.8%, 33.3%, and 24.0% in patients with macroalbuminuria, microalbuminuria, and normoalbuminuria, respectively.

Study details: This was a cross-sectional study including 200 patients with T2D, of which 100, 66, and 34 had normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively.

Disclosures: This study was supported by Shiraz University of Medical Sciences, Iran. The authors declared no competing interests.

Source: Zomorodian SA et al. Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus. BMC Endocr Disord. 2022;22:171 (Jul 4). Doi: 10.1186/s12902-022-01088-2

Key clinical point: Serum level of 25-hydroxyvitamin D (25[OH]D) was inversely associated with albuminuria as an indicator of diabetic nephropathy in patients with type 2 diabetes mellitus (T2D), with the prevalence of macroalbuminuria increasing when the serum 25(OH)D level was <20 ng/mL.

Major finding: A strong negative association was observed between the serum 25(OH)D level and severity of albuminuria (r, −0.257; P < .001), with the prevalence of vitamin D deficiency being 61.8%, 33.3%, and 24.0% in patients with macroalbuminuria, microalbuminuria, and normoalbuminuria, respectively.

Study details: This was a cross-sectional study including 200 patients with T2D, of which 100, 66, and 34 had normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively.

Disclosures: This study was supported by Shiraz University of Medical Sciences, Iran. The authors declared no competing interests.

Source: Zomorodian SA et al. Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus. BMC Endocr Disord. 2022;22:171 (Jul 4). Doi: 10.1186/s12902-022-01088-2

Key clinical point: Serum level of 25-hydroxyvitamin D (25[OH]D) was inversely associated with albuminuria as an indicator of diabetic nephropathy in patients with type 2 diabetes mellitus (T2D), with the prevalence of macroalbuminuria increasing when the serum 25(OH)D level was <20 ng/mL.

Major finding: A strong negative association was observed between the serum 25(OH)D level and severity of albuminuria (r, −0.257; P < .001), with the prevalence of vitamin D deficiency being 61.8%, 33.3%, and 24.0% in patients with macroalbuminuria, microalbuminuria, and normoalbuminuria, respectively.

Study details: This was a cross-sectional study including 200 patients with T2D, of which 100, 66, and 34 had normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively.

Disclosures: This study was supported by Shiraz University of Medical Sciences, Iran. The authors declared no competing interests.

Source: Zomorodian SA et al. Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus. BMC Endocr Disord. 2022;22:171 (Jul 4). Doi: 10.1186/s12902-022-01088-2

Key clinical point: The sarcopenia index (SI; serum creatinine/serum cystatin C ratio) is significantly associated with the prevalence of subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2D).

Major finding: After adjusting for all confounders, SI was significantly associated with the prevalence of subclinical atherosclerosis (adjusted odds ratio 0.95; P  =  .015).

Study details: The data come from a cross-sectional study of 174 patients with T2D, of which 43.7% were diagnosed with subclinical atherosclerosis.

Disclosures: The study received no specific funding. Some authors declared receiving honoraria, personal fees, r research grants from various sources.

Source: Hashimoto Y et al. Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2022;10:e002910 (Jun 23). Doi: 10.1136/bmjdrc-2022-002910

Key clinical point: The sarcopenia index (SI; serum creatinine/serum cystatin C ratio) is significantly associated with the prevalence of subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2D).

Major finding: After adjusting for all confounders, SI was significantly associated with the prevalence of subclinical atherosclerosis (adjusted odds ratio 0.95; P  =  .015).

Study details: The data come from a cross-sectional study of 174 patients with T2D, of which 43.7% were diagnosed with subclinical atherosclerosis.

Disclosures: The study received no specific funding. Some authors declared receiving honoraria, personal fees, r research grants from various sources.

Source: Hashimoto Y et al. Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2022;10:e002910 (Jun 23). Doi: 10.1136/bmjdrc-2022-002910

Key clinical point: The sarcopenia index (SI; serum creatinine/serum cystatin C ratio) is significantly associated with the prevalence of subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2D).

Major finding: After adjusting for all confounders, SI was significantly associated with the prevalence of subclinical atherosclerosis (adjusted odds ratio 0.95; P  =  .015).

Study details: The data come from a cross-sectional study of 174 patients with T2D, of which 43.7% were diagnosed with subclinical atherosclerosis.

Disclosures: The study received no specific funding. Some authors declared receiving honoraria, personal fees, r research grants from various sources.

Source: Hashimoto Y et al. Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2022;10:e002910 (Jun 23). Doi: 10.1136/bmjdrc-2022-002910

Key clinical point: In patients with type 2 diabetes (T2D), initiating or switching to insulin degludec/ aspart (IDegAsp) from other antidiabetic treatments was associated with improved glycemic control, lower basal insulin dose requirement in insulin-experienced patients, and lower rates of hypoglycemia.

Major finding: Patients with T2D initiating or switching to IDegAsp had a significant reduction in glycated hemoglobin (estimated difference [Δ] −1.4%; P < .0001), basal insulin dose requirements in insulin-experienced participants (Δ −2.3 units; P  =  .0004), and rates of hypoglycemia (P < .001).

Study details: Findings are from a real-world, prospective study including 1102 patients with T2D who initiated or switched to IDegAsp from other antidiabetic treatments.

Disclosures: This study was funded by Novo Nordisk. Some authors declared being employees and shareholders of Novo Nordisk. Some authors declared receiving speaker or consulting honoraria, research contracts, and teaching or research sponsorships; being consultants; or serving as advisory board or speaker panel members for various sources, including Novo Nordisk.

Source: Fulcher GR et al. Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes: A real-world, prospective, non-interventional study across six countries. Adv Ther. 2022 (Jun 25). Doi: 10.1007/s12325-022-02212-3

Key clinical point: In patients with type 2 diabetes (T2D), initiating or switching to insulin degludec/ aspart (IDegAsp) from other antidiabetic treatments was associated with improved glycemic control, lower basal insulin dose requirement in insulin-experienced patients, and lower rates of hypoglycemia.

Major finding: Patients with T2D initiating or switching to IDegAsp had a significant reduction in glycated hemoglobin (estimated difference [Δ] −1.4%; P < .0001), basal insulin dose requirements in insulin-experienced participants (Δ −2.3 units; P  =  .0004), and rates of hypoglycemia (P < .001).

Study details: Findings are from a real-world, prospective study including 1102 patients with T2D who initiated or switched to IDegAsp from other antidiabetic treatments.

Disclosures: This study was funded by Novo Nordisk. Some authors declared being employees and shareholders of Novo Nordisk. Some authors declared receiving speaker or consulting honoraria, research contracts, and teaching or research sponsorships; being consultants; or serving as advisory board or speaker panel members for various sources, including Novo Nordisk.

Source: Fulcher GR et al. Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes: A real-world, prospective, non-interventional study across six countries. Adv Ther. 2022 (Jun 25). Doi: 10.1007/s12325-022-02212-3

Key clinical point: In patients with type 2 diabetes (T2D), initiating or switching to insulin degludec/ aspart (IDegAsp) from other antidiabetic treatments was associated with improved glycemic control, lower basal insulin dose requirement in insulin-experienced patients, and lower rates of hypoglycemia.

Major finding: Patients with T2D initiating or switching to IDegAsp had a significant reduction in glycated hemoglobin (estimated difference [Δ] −1.4%; P < .0001), basal insulin dose requirements in insulin-experienced participants (Δ −2.3 units; P  =  .0004), and rates of hypoglycemia (P < .001).

Study details: Findings are from a real-world, prospective study including 1102 patients with T2D who initiated or switched to IDegAsp from other antidiabetic treatments.

Disclosures: This study was funded by Novo Nordisk. Some authors declared being employees and shareholders of Novo Nordisk. Some authors declared receiving speaker or consulting honoraria, research contracts, and teaching or research sponsorships; being consultants; or serving as advisory board or speaker panel members for various sources, including Novo Nordisk.

Source: Fulcher GR et al. Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes: A real-world, prospective, non-interventional study across six countries. Adv Ther. 2022 (Jun 25). Doi: 10.1007/s12325-022-02212-3

Key clinical point: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in patients with type 2 diabetes mellitus (T2D) is associated with a significantly lower risk for all-cause and cause-specific death compared with dipeptidyl peptidase 4 inhibitor (DPP4i) use.

Major finding: Patients receiving SGLT2i vs DPP4i had a lower risk for all-cause death (adjusted hazard ratio [aHR] 0.66; P < .001), cardiovascular death (aHR 0.68; P < .001), cancer death (aHR 0.73; P  =  .003), and noncancer and nonvascular death (aHR 0.62; P < .001).

Study details: This nationwide retrospective cohort study matched patients with T2D who initiated SGLT2i (n = 53,264) with those who initiated DPP4i (n = 53,264) using propensity score matching.

Disclosures: This study was partly supported by grants from China Medical University Hospital, Ditmanson Medical Foundation Chiayi Christian Hospital, and the Ministry of Science and Technology of Taiwan. No competing interests were declared.

Source: Chung M-C et al. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial. Sci Rep. 2022;12:10147 (Jun 16). Doi: 10.1038/s41598-022-13760-7

Key clinical point: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in patients with type 2 diabetes mellitus (T2D) is associated with a significantly lower risk for all-cause and cause-specific death compared with dipeptidyl peptidase 4 inhibitor (DPP4i) use.

Major finding: Patients receiving SGLT2i vs DPP4i had a lower risk for all-cause death (adjusted hazard ratio [aHR] 0.66; P < .001), cardiovascular death (aHR 0.68; P < .001), cancer death (aHR 0.73; P  =  .003), and noncancer and nonvascular death (aHR 0.62; P < .001).

Study details: This nationwide retrospective cohort study matched patients with T2D who initiated SGLT2i (n = 53,264) with those who initiated DPP4i (n = 53,264) using propensity score matching.

Disclosures: This study was partly supported by grants from China Medical University Hospital, Ditmanson Medical Foundation Chiayi Christian Hospital, and the Ministry of Science and Technology of Taiwan. No competing interests were declared.

Source: Chung M-C et al. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial. Sci Rep. 2022;12:10147 (Jun 16). Doi: 10.1038/s41598-022-13760-7

Key clinical point: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in patients with type 2 diabetes mellitus (T2D) is associated with a significantly lower risk for all-cause and cause-specific death compared with dipeptidyl peptidase 4 inhibitor (DPP4i) use.

Major finding: Patients receiving SGLT2i vs DPP4i had a lower risk for all-cause death (adjusted hazard ratio [aHR] 0.66; P < .001), cardiovascular death (aHR 0.68; P < .001), cancer death (aHR 0.73; P  =  .003), and noncancer and nonvascular death (aHR 0.62; P < .001).

Study details: This nationwide retrospective cohort study matched patients with T2D who initiated SGLT2i (n = 53,264) with those who initiated DPP4i (n = 53,264) using propensity score matching.

Disclosures: This study was partly supported by grants from China Medical University Hospital, Ditmanson Medical Foundation Chiayi Christian Hospital, and the Ministry of Science and Technology of Taiwan. No competing interests were declared.

Source: Chung M-C et al. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial. Sci Rep. 2022;12:10147 (Jun 16). Doi: 10.1038/s41598-022-13760-7

Key clinical point: Prusogliptin as an add-on therapy to metformin was superior to metformin monotherapy in improving glycemic control and was safe and well tolerated in patients with type 2 diabetes mellitus (T2D) inadequately controlled with metformin.

Major finding: At week 24, prusogliptin + metformin vs metformin + placebo led to significantly higher reductions in glycated hemoglobin (least squares mean change [LSM] −0.70% vs −0.07%; P < .001), fasting plasma glucose (LSM −0.63 vs 0.07 mmol/L; P  =  .025), and 2-hour postprandial plasma glucose (LSM −2.43 vs −0.70 mmol/L; P < .001) levels, with the incidence of adverse events being similar between the treatment groups.

Study details: Findings are from a 24-week, superiority, phase 3 trial including 206 patients with T2D with blood glucose levels inadequately controlled on metformin who were randomly assigned to receive prusogliptin + metformin (n = 138) or placebo + metformin (n = 68).

Disclosures: This study was funded by the CSPC Zhongqi Pharmaceutical Technology Co., Ltd. Some authors are employees of CSPC Zhongqi Pharmaceutical Technology.

Source: Xu J et al. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial. Diabetes Obes Metab. 2022 (Jul 6). Doi: 10.1111/dom.14810

Key clinical point: Prusogliptin as an add-on therapy to metformin was superior to metformin monotherapy in improving glycemic control and was safe and well tolerated in patients with type 2 diabetes mellitus (T2D) inadequately controlled with metformin.

Major finding: At week 24, prusogliptin + metformin vs metformin + placebo led to significantly higher reductions in glycated hemoglobin (least squares mean change [LSM] −0.70% vs −0.07%; P < .001), fasting plasma glucose (LSM −0.63 vs 0.07 mmol/L; P  =  .025), and 2-hour postprandial plasma glucose (LSM −2.43 vs −0.70 mmol/L; P < .001) levels, with the incidence of adverse events being similar between the treatment groups.

Study details: Findings are from a 24-week, superiority, phase 3 trial including 206 patients with T2D with blood glucose levels inadequately controlled on metformin who were randomly assigned to receive prusogliptin + metformin (n = 138) or placebo + metformin (n = 68).

Disclosures: This study was funded by the CSPC Zhongqi Pharmaceutical Technology Co., Ltd. Some authors are employees of CSPC Zhongqi Pharmaceutical Technology.

Source: Xu J et al. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial. Diabetes Obes Metab. 2022 (Jul 6). Doi: 10.1111/dom.14810

Key clinical point: Prusogliptin as an add-on therapy to metformin was superior to metformin monotherapy in improving glycemic control and was safe and well tolerated in patients with type 2 diabetes mellitus (T2D) inadequately controlled with metformin.

Major finding: At week 24, prusogliptin + metformin vs metformin + placebo led to significantly higher reductions in glycated hemoglobin (least squares mean change [LSM] −0.70% vs −0.07%; P < .001), fasting plasma glucose (LSM −0.63 vs 0.07 mmol/L; P  =  .025), and 2-hour postprandial plasma glucose (LSM −2.43 vs −0.70 mmol/L; P < .001) levels, with the incidence of adverse events being similar between the treatment groups.

Study details: Findings are from a 24-week, superiority, phase 3 trial including 206 patients with T2D with blood glucose levels inadequately controlled on metformin who were randomly assigned to receive prusogliptin + metformin (n = 138) or placebo + metformin (n = 68).

Disclosures: This study was funded by the CSPC Zhongqi Pharmaceutical Technology Co., Ltd. Some authors are employees of CSPC Zhongqi Pharmaceutical Technology.

Source: Xu J et al. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial. Diabetes Obes Metab. 2022 (Jul 6). Doi: 10.1111/dom.14810

Key clinical point: Initiation of semaglutide in patients with type 2 diabetes mellitus (T2D) on high daily doses of insulin at baseline led to a significant improvement in glycemic control, body weight, and reduction in total daily dose (TDD) of insulin.

Major finding: From baseline to 6 months, the TDD of insulin (183 ± 98 to 143 ± 99 units, respectively), glycated hemoglobin level (8.9% ± 1.3% to 7.6% ± 1.5%, respectively), and body weight (123.9 ± 23.5 to 118.9 ± 22.9 kg, respectively; all P < .001) reduced significantly in patients on high daily doses of insulin who received semaglutide.

Study details: Findings are from a retrospective analysis including 72 patients with T2D on high TDD of insulin (≥100 units) who were prescribed semaglutide.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Meyer J et al. The effects of adding semaglutide to high daily dose insulin regimens in patients with type 2 diabetes. Ann Pharmacother. 2022 (Jul 1). Doi: 10.1177/10600280221107381

Key clinical point: Initiation of semaglutide in patients with type 2 diabetes mellitus (T2D) on high daily doses of insulin at baseline led to a significant improvement in glycemic control, body weight, and reduction in total daily dose (TDD) of insulin.

Major finding: From baseline to 6 months, the TDD of insulin (183 ± 98 to 143 ± 99 units, respectively), glycated hemoglobin level (8.9% ± 1.3% to 7.6% ± 1.5%, respectively), and body weight (123.9 ± 23.5 to 118.9 ± 22.9 kg, respectively; all P < .001) reduced significantly in patients on high daily doses of insulin who received semaglutide.

Study details: Findings are from a retrospective analysis including 72 patients with T2D on high TDD of insulin (≥100 units) who were prescribed semaglutide.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Meyer J et al. The effects of adding semaglutide to high daily dose insulin regimens in patients with type 2 diabetes. Ann Pharmacother. 2022 (Jul 1). Doi: 10.1177/10600280221107381

Key clinical point: Initiation of semaglutide in patients with type 2 diabetes mellitus (T2D) on high daily doses of insulin at baseline led to a significant improvement in glycemic control, body weight, and reduction in total daily dose (TDD) of insulin.

Major finding: From baseline to 6 months, the TDD of insulin (183 ± 98 to 143 ± 99 units, respectively), glycated hemoglobin level (8.9% ± 1.3% to 7.6% ± 1.5%, respectively), and body weight (123.9 ± 23.5 to 118.9 ± 22.9 kg, respectively; all P < .001) reduced significantly in patients on high daily doses of insulin who received semaglutide.

Study details: Findings are from a retrospective analysis including 72 patients with T2D on high TDD of insulin (≥100 units) who were prescribed semaglutide.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Meyer J et al. The effects of adding semaglutide to high daily dose insulin regimens in patients with type 2 diabetes. Ann Pharmacother. 2022 (Jul 1). Doi: 10.1177/10600280221107381

Key clinical point: Dipeptidyl peptidase-4 (DPP4) inhibitors significantly increased the risk for the composite of gallbladder or biliary diseases and cholecystitis but not for cholelithiasis and biliary diseases in patients with type 2 diabetes (T2D), especially those with a longer treatment duration.

Major finding: Compared with placebo or non-incretin drugs, DPP4 inhibitors were associated with a significantly higher risk for composite of gallbladder or biliary diseases (odds ratio [OR] 1.22; 95% CI 1.04-1.43) and cholecystitis (OR 1.43; 95% CI 1.14-1.79), but not for cholelithiasis (OR 1.08; 95% CI 0.83-1.39) and biliary diseases (OR 1.00; 95% CI 0.68-1.47), and the association remained significant with the long-term (≥26 weeks) use of DPP4 inhibitors.

Study details: The data come from a systematic review and pairwise meta-analysis of 82 randomized trials including 104,833 patients with T2D.

Disclosures: This study was partially supported by Beijing Natural Science Foundation, National Natural Science Foundation of China, and others. The authors declared receiving support from the funding institutions.

Source: He L et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials BMJ. 2022;377:e068882 (Jun 28). Doi: 10.1136/bmj-2021-068882

Key clinical point: Dipeptidyl peptidase-4 (DPP4) inhibitors significantly increased the risk for the composite of gallbladder or biliary diseases and cholecystitis but not for cholelithiasis and biliary diseases in patients with type 2 diabetes (T2D), especially those with a longer treatment duration.

Major finding: Compared with placebo or non-incretin drugs, DPP4 inhibitors were associated with a significantly higher risk for composite of gallbladder or biliary diseases (odds ratio [OR] 1.22; 95% CI 1.04-1.43) and cholecystitis (OR 1.43; 95% CI 1.14-1.79), but not for cholelithiasis (OR 1.08; 95% CI 0.83-1.39) and biliary diseases (OR 1.00; 95% CI 0.68-1.47), and the association remained significant with the long-term (≥26 weeks) use of DPP4 inhibitors.

Study details: The data come from a systematic review and pairwise meta-analysis of 82 randomized trials including 104,833 patients with T2D.

Disclosures: This study was partially supported by Beijing Natural Science Foundation, National Natural Science Foundation of China, and others. The authors declared receiving support from the funding institutions.

Source: He L et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials BMJ. 2022;377:e068882 (Jun 28). Doi: 10.1136/bmj-2021-068882

Key clinical point: Dipeptidyl peptidase-4 (DPP4) inhibitors significantly increased the risk for the composite of gallbladder or biliary diseases and cholecystitis but not for cholelithiasis and biliary diseases in patients with type 2 diabetes (T2D), especially those with a longer treatment duration.

Major finding: Compared with placebo or non-incretin drugs, DPP4 inhibitors were associated with a significantly higher risk for composite of gallbladder or biliary diseases (odds ratio [OR] 1.22; 95% CI 1.04-1.43) and cholecystitis (OR 1.43; 95% CI 1.14-1.79), but not for cholelithiasis (OR 1.08; 95% CI 0.83-1.39) and biliary diseases (OR 1.00; 95% CI 0.68-1.47), and the association remained significant with the long-term (≥26 weeks) use of DPP4 inhibitors.

Study details: The data come from a systematic review and pairwise meta-analysis of 82 randomized trials including 104,833 patients with T2D.

Disclosures: This study was partially supported by Beijing Natural Science Foundation, National Natural Science Foundation of China, and others. The authors declared receiving support from the funding institutions.

Source: He L et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials BMJ. 2022;377:e068882 (Jun 28). Doi: 10.1136/bmj-2021-068882